Consumer healthcare manufacturer expands with acquisition
West Yorkshire-based Fen Group has consolidated its position in the UK cannabidiol (CBD) market with a new acquisition deal.
Its purchase of White Label 360 is intended to significantly enhance the Group’s contract manufacturing offering.
Fen Group is a consumer healthcare manufacturer specialising in cannabis-derived wellness products, based in Halifax.
It explains this deal is the first in what should be a string of strategic acquisitions as it seeks to become the dominant player in the UK CBD market.
White Label 360 is a CBD contract manufacturing firm based in Barnsley, with a substantial portfolio of clients, and a broad product offering.
Colin O’Donnell, CEO of White Label 360, said: “I am looking forward to working with Fen Group as they endeavour to bring structure into such a fragmented CBD market in the UK.”
Along with White Label 360’s contract manufacturing business, Fen Group is also acquiring its flagship brand, CBDeaze, which has been trading in the market since 2015.
This deal also opens up potential distribution channels in Germany and South Africa.
Tom Fennell, CEO of Fen Group, added: “This acquisition allows Fen Group to rapidly increase our revenues, whilst keeping our core value proposition consistent, we are very excited to build on the foundational work that Colin has put in.”